Heart 2009;95:1-3
FEATURED EDITORIAL
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
1 Section on General Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
2 Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
Dr S Singh, Wake Forest University School of Medicine, One Medical Center Blvd, Winston-Salem, NC 27157, USA; sosingh@wfubmc.edu
| The first 150 words of the full text of this article appear below. |
Patients with type 2 diabetes experience high rates of comorbid conditions such as hypertension and dyslipidaemia that further compound their already increased risk of developing ischaemic heart disease (IHD). IHD and hypertension, in turn, represent conditions that are major precursors of congestive heart failure (CHF), adding to the cardiovascular disease (CVD) burden in this patient population. This is reflected in the reported estimate of IHD prevalence in diabetics (approximating 22%)1 and the reported 10-year incidence of CHF among elderly patients with newly diagnosed type 2 diabetes (exceeding 50%).2 The American Heart Association and the American Diabetes Association have also noted in a joint scientific statement paper that CVD contributes to more than three-quarters of all deaths in diabetic patients.3
S Singh
| |||||||||
The health benefits of treating hypertension with angiotensin-converting enzyme inhibitors4 and treating hyperlipidaemia with statins5 have been well established in clinical trials. The use of other preventive measures such
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Kaneda, H, Shiono, T, Miyashita, Y, Takahashi, S, Taketani, Y, Domae, H, Matsumi, J, Mizuno, S, Minami, Y, Sugitatsu, K, Saito, S
(2009). Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart
95: 1079-1084
[Abstract] [Full Text]
eLetters:
Read all eLetters
- Thiazolidinediones and cardiovascular disease
- Peter J Grant
- Online, 4 Sep 2008 [Full text]
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
hrt.2008.155507v1
hrt.2008.155507v2
95/1/1 most recent - Submit a response
- Read responses to this article
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
